ROTH Capital Partners, a full service investment bank focused on serving emerging growth companies and their investors, has promoted Yasmeen Rahimi, Ph.D., managing director and senior research analyst, to the role of co-head of Biotechnology Research.
Rahimi has been a senior research analyst at ROTH since 2017, covering companies that are developing therapeutics to treat various liver diseases and conditions, including Nonalcoholic Steatohepatitis (NASH). She also covers companies that are developing products aligned in the orphan and ultra-orphan therapeutics, as well as women’s health.
Rahimi has extensive expertise in NASH and liver metabolism with 16 publications in highly prestigious journals. She trained at Yale University in the laboratory of Dr. Gerald Shulman, a world-renowned endocrinologist who pioneered the understanding of lipid-induced insulin resistance. In addition, she completed her Ph.D. training in the laboratory of Dr. Robert A. Harris, a distinguished biochemist at Indiana University.
Jeff Martin, CFA, director of research, commented, “I am pleased to have Dr. Rahimi and Dr. Tony Butler leading our biotech research effort. We have made a commitment of resources to the sector, to support the companies making the scientific advancements that will help find cures and treatments for some of the most debilitating diseases.”
Rahimi stated, “I am grateful to ROTH for this promotion and continued investment in fostering innovation and creativity in healthcare. I look forward to working with my fellow research analysts and associates and the entire ROTH team to create impactful and specially designed research across various therapeutics areas.”
“Dr. Rahimi has demonstrated passion, credibility, and initiative to promote the ROTH healthcare practice that is rare for a person with her relatively few years of experience,” said Byron Roth, CEO of ROTH Capital Partners. “She has earned this promotion, and we look forward to working with her for years to come.”
Since 2010, ROTH has completed over 400 transactions for healthcare companies, raising over $16 billion in growth capital.
